This is particularly imperative in certain malignancies, such as breast cancer, where it has been shown that ANXA1 can behave as both a tumour suppressor (e.g. in oestrogen receptor+ breast cancers that generally have low ANXA1 levels) and an oncogene (e.g. in basal‐like breast cancer where ANXA1 is highly expressed), with levels of expression dependent on tissue and cell type [93, 94. Here, ANXA1 is linked to breast carcinoma.